IntelGenx Corp.
Leader in pharmaceutical films
Leader in pharmaceutical films
IntelGenx, Advancing pharmaceutical innovation with comprehensive oral film solutions, is a biotechnology and pharmaceutical startup that specializes in oral drug delivery. Established in 2003, the company's primary focus is on developing and manufacturing innovative pharmaceutical oral films through its proprietary VersaFilm™ technology platform. IntelGenx offers extensive pharmaceutical services to its partners, including R&D, analytical method development, clinical monitoring, intellectual property, and regulatory support. With a recent $3.00M Post-IPO Equity investment at 31 August 2023 from ATAI Life Sciences, the company is well-positioned to further advance its technological capabilities and expand its market presence in the biotechnology and pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $3.00M | 1 |
|
31 Aug 2023 |
| Post-IPO Equity | $3.50M | - | 16 Dec 2013 |
No recent news or press coverage available for IntelGenx Corp..
We care about your data, and we'd love to use cookies make your experience better.
